SCHEMBL4315513

SCHEMBL4315513

COc1c(OCCN2CCCC2=O)ccc(C=Cc2n[nH]c3ccccc23)c1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK1 P28482 1/20 0.39
KIT P10721 4/20 0.37
KDR P35968 2/20 0.37
FLT3 P36888 2/20 0.37
CTSS P25774 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 2/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
BRD4 O60885 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315506 1.00 MEN1 (0.45) MEN1KMT2AMAPK1KITKDR
SCHEMBL4315410 0.87 MEN1 (0.42) MEN1KMT2AMAPK1KITKDR
SCHEMBL4315419 0.87 MEN1 (0.42) MEN1KMT2AMAPK1KITKDR
SCHEMBL4322021 0.81 CHEK1 (0.37) KMT2AKDRL3MBTL1RAB9ASMN1; SMN2
SCHEMBL4314415 0.81 CHEK1 (0.37) KMT2AKDRL3MBTL1RAB9ASMN1; SMN2
SCHEMBL4314405 0.81 CHEK1 (0.37) KMT2AKDRL3MBTL1RAB9ASMN1; SMN2
SCHEMBL4322028 0.81 CHEK1 (0.37) KMT2AKDRL3MBTL1RAB9ASMN1; SMN2
SCHEMBL4312077 0.80 AURKA (0.44) MEN1KMT2AMAPK1KITKDR
SCHEMBL4312069 0.80 AURKA (0.44) MEN1KMT2AMAPK1KITKDR
SCHEMBL4320803 0.78 TP53 (0.45) MEN1KMT2AMAPK1KITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 MEN1 1830/4885KMT2A 1924/4885MAPK1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.